Analysis of 2 642 reports of adverse reactions related to carbapenems and risk signal mining

Published on Mar. 05, 2024Total Views: 663 times Total Downloads: 544 times Download Mobile

Author: LI Haiyan ^1, ²  GUO Daihong ^2, ³ YUAN Yonghua ¹ ZHU Man ³ GAO Ao ^2, ³ LU Jingchuan ^1, ² FU An ^2, ³ LI Chao ^2, ³ LI Peng ^2, ³ ZHAO Anqi ^2, ³

Affiliation: 1. College of Pharmacy, Chongqing Medical University, Chongqing 400016, China 2. Adverse Drug Reaction Monitoring Center, Chinese PLA General Hospital, Beijing 100853, China 3. Department of Pharmacy, Medical Supplies Center of Chinese PLA General Hospital, Beijing 100853, China

Keywords: Carbapenems Antibacterial drugs Adverse drug reactions Data mining Retrospective analysis

DOI: 10.12173/j.issn.1005-0698.202305051

Reference: LI Haiyan, GUO Daihong, YUAN Yonghua, ZHU Man, GAO Ao, LU Jingchuan, FU An,LI Chao, LI Peng, ZHAO Anqi.Analysis of 2 642 reports of adverse reactions related to carbapenems and risk signal mining[J].Yaowu Liuxingbingxue Zazhi,2024, 33(3):251-258.DOI: 10.12173/j.issn.1005-0698.202305051.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To understand the incidence and characteristics of adverse drug reactions (ADRs) of carbapenems, explore the relevant risk signals, and provide a reference for clinically safe drug use.

Methods All spontaneous reports of carbapenem drug-related ADRs from January 2008 to October 2022 in the Adverse Drug Reaction Monitoring Center, PLA General Hospital's ADR database were retrieved, and information such as patients' general conditions, involved systems and organs damage, and the names of ADRs involved were retrospectively analysed. Using the reporting odd ratio method, the proportional reporting ratio method, the Medicines and Healthcare Products Regulatory Agency method, and information component method to obtain risk signals of carbapenem antimicrobial drug-related ADR.

Results A total of 2 642 ADR reports of carbapenems were reported, of which 410 serious ADR reports (15.52%) were serious ADR reports, five cabapenem antimirobial drug species were mainly involved. In descending order of composition were imipenem cilastatin (51.28%), meropenem (32.13%), biapenem (8.10%), ertapenem (7.68%), and panipenem (0.79%). The male to female ratio of patients was 1.74 ∶ 1, with the most age > 60 years (59.69%). A total of 14 "drug-ADR name" combinations generated risk signals in all four data mining methods, with meropenem being the most signals, and imipenem cilastatin and ertapenem had a high number of reported ADR in nervous system.

Conclusion The results of risk signal mining are basically consistent with the known carbapenem ADR information, during the use of carbapenem antimicrobial drugs in the clinic, it is recommended to monitor patients' liver and kidney functions as well as blood biochemical indexes, so as to strengthen the awareness of vigilance in the clinical use of carbapenem antimicrobial drugs, and timely recognize and deal with ADRs in a timely manner, and to avoid the occurrence of serious ADRs.

Full-text

Please download the PDF version to read the full text: download

References

1.滕蒙蒙,孙丹,韩瑞英,等.碳青霉烯类在抗感染治疗中给药方案优化研究进展[J].中国药学杂志, 2020, 55(21): 1762-1767. [Teng MM, Sun D, Han RY, et al. Research progress on optimization of carbapenem dosage regimen in critically ill patients[J]. Chinese Pharmaceutical Journal, 2020, 55(21): 1762-1767.] DOI: 10.11669/cpj.2020.21.003.

2.王艳玲,何瑞红,王丹，等.抗菌药物规范化给药频次现状调查及分析[J].临床合理用药杂志, 2019, 12(5): 104. [Wang YL, He RH, Wang D, et al. Survey and analysis of the current status of standardised frequency of antimicrobial drug administration[J]. Journal of Clinical Rational Drug Use, 2019, 12(5): 104.] DOI: CNKI:SUN:PLHY.0.2019-05-190.

3.朱曼,凡超,郭代红,等. 军队医院1175例抗感染药物严重药品不良反应/事件报告分析[J].中国药物应用与监测, 2015, 12(3): 163-167. [Zhu M, Fan C, Guo DH, et al. Analysis of 1175 cases of serious adverse drug reactions/events reported for anti-infective drugs in military hospitals[J]. Chinese Journal of Drug Application and Monitoring, 2015, 12(3): 163-167.] DOI: CNKI:SUN:YWYY.0.2015-03-012.

4.刘晶,谢雁鸣,盖国忠,等.药品不良反应术语集WHOART与MedDRA的应用探析[J].中国中药杂志, 2015, 40(24): 4728-4733. [Liu J, Xie YM, Gai GZ, et al. Application analysis of adverse drug reaction terminology WHOART and MedDRA[J]. China Journal of Chinese Materia Medica, 2015, 40(24): 4728-4733.] DOI: 10.4268/cjcmm20152402.

5.郭代红, 朱曼, 徐元杰, 等. 信息化军队药物警戒系统的构建与应用[J]. 解放军药学学报, 2023, 36(2): 95-99. [Guo DH, Zhu M, Xu YJ, et al. Construction and application of informationized military drug surveillance system[J]. Pharmaceutical Journal of Chinese People's Liberation Army, 2023, 36(2): 95-99.] DOI: 10.3969/j.issn.1008-9926.2023.02.001.

6.侯永芳,王玲,郭秀花,等.信号检测在药品不良反应监测系统中的应用[J].中国药物警戒, 2012, 9(9): 539-541. [Hou YF, Wang L, Guo XH, et al. Signal detection in the software for adverse drug reaction monitoring[J]. Chinese Journal of Pharmacovigilance, 2012, 9(9): 539-541.] DOI: CNKI:SUN:YWJJ.0.2012-09-009.

7.张千, 颜明明, 赵晖, 等.基于FAERS数据库芬戈莫德在多发性硬化患者中的肿瘤风险信号挖掘[J]. 药物流行病学杂志, 2023, 32(9): 961-968. [Zhang Q, Yan MM, Zhao H, et al. Data mining of cancer risk associated with fingolimod in multiple sclerosis patients: based on FAERS database[J]. Chinese Journal of Pharmacoepidemiology, 2023, 32(9): 961-968.] DOI: 10.19960/j.issn.1005-0698.202309001.

8.赵媛媛,王屏,银洪汝. 碳青霉烯类抗菌药物致不良反应文献分析[J].中国药房, 2013, 24(10): 933-935. [Zhao YY, Yu P, Ying HR. Carbapenem antibacterial drugs induced adverse drug reaction[J]. China Pharmacy, 2013, 24(10): 933-935.] DOI: 10.6039/j.issn.1001-0408.2013.10.27.

9.蒋荣猛,宋美华.关注特殊人群抗菌药物应用的安全性[J].药物不良反应杂志, 2020, 22(1): 2-5. [Jiang RM, Song MH. Pay attention to the safety of application of antibacterials in special population[J]. Adverse Drug Reactions Journal, 2020, 22(1): 2-5.] DOI: 10.3760/cma.j.issn.1008-5734.2020.01.002.

10.倪文骐,熊琪,袁凤仪,等.亚胺培南/西司他丁致中枢神经系统不良反应的文献分析[J]. 中国临床保健杂志, 2022, 25(1): 91-94. [Ni WQ, Xiong Q, Yuan FY, et al. Literature analysis of adverse drug reaction on central nervous system induced by imipenem/cilastatin[J]. Chinese Journal of Clinical Health Care, 2022, 25(1): 91-94.] DOI: 10.3969/J.issn.1672-6790.2022.01.021.

11.王广飞,李静,卢金淼,等.碳青霉烯类抗菌药物致药品不良反应报告[J].中国医院用药评价与分析, 2017, 17(6): 830-832, 835. [Wang GF, Li J, Lu JM, et al. Reports of adverse drug reactions induced by carbapenem antibiotics[J]. Chinese Journal of Hospital Drug Evaluation and Analysis, 2017, 17(6): 830-832, 835.] DOI: 10.14009/j.issn.1672-2124.2017.06.039.

12.陈聪聪,董博.某院24例亚胺培南/西司他丁不良反应报告分析[J]. 中国处方药, 2021, 19(2): 61-62. [Chen CC, Dong B. Analysis of 24 adverse reactions of imipenem-cilastatin in a hospital[J]. Chinese Journal of Prescription Drugs, 2021, 19(2): 61-62.] DOI: 10.3969/j.issn.1671-945X.2021.02.029.

13.唐春梅,杨思芸,詹阳洋,等. 基于FAERS数据库的3种碳青霉烯类药物不良反应信号挖掘研究[J].中南药学, 2021, 19(12): 2576-2581. [Tang CM, Yang SY, Zhan YY, et al. Adverse drug reaction signals of 3 carbapenems based on the FAERS database[J]. Central South Pharmacy, 2021, 19(12): 2576-2581.] DOI: 10.7539/j.issn.1672-2981.2021.12.019.

14.The U. S. Food and drug administration. MEROPENEM for injection AND SODIUM CHLORIDE injection, for intravenous use Labeling-Package Insert SUPPL-40[EB/OL]. (2018-06-05) [2023-07-01]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202106s007lbl.pdf.

15.Holt MP, Ju C. Mechanisms of drug-induced liver injury[J].AAPS J, 2006, 8(1): E48-54. DOI: 10.1208/aapsj080106.

16.赵美,党学良,孙涛,等.美罗培南对住院患者肝功能影响的回顾性调查[J].药物流行病学杂志, 2021, 30(2): 933-935. [Zhao M, Dang XL, Sun T, et al. Retrospective analysis on liver function of patients used meropenem for injection[J]. Chinese Journal of Pharmacoepidemiology, 2021, 30(2): 933-935.] DOI: 10.19960/j.cnki.issn1005-0698.2021.02.005.

17.Ninan J, George GM. Imipenem-cilastatin-induced psychosis: a case report[J]. J Med Case Rep, 2016, 10(1): 107. DOI: 10.1186/s13256-016-0883-x.

18.任晓蕾,詹轶秋,张春燕,等. 6例厄他培南致神经系统不良反应报告分析[J].中国医院用药评价与分析, 2020, 20(2): 243-245. [Ren XL, Zhan YQ, Zhang CY, et al. Analysis of 6 cases of neurological adverse drug reactions induced by ertapenem[J]. Evaluation and Analysis of Drug Use in Chinese Hospitals, 2020, 20(2): 243-245.] DOI: 10.14009/j.issn.1672-2124.2020.02.031.

19.Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside[J]. Eur J Clin Microbiol Infect Dis, 2005, 24: 649-653. DOI: 10.1007/s10096-005-0021-y.

20.Vardakas KZ, Kalimeris GD, Triarides NA, et al. An update on adverse drug reactions related to β-lactam antibiotics[J]. Expert Opin Drug Saf, 2018, 17(5): 499-508. DOI: 10.1080/14740338.2018.1462334.

21.温爱萍,李丹丹,鲍晓龙.亚胺培南/西司他丁致成人危重症患者中枢神经系统不良反应发生情况及其危险因素分析[J].中国药物应用与监测, 2019, 16(2): 89-92. [Wen AP, Li DD, Bao XL. Occurrence and the risk factors of adverse drug reactions of central nervous system induced by imipenem/cilastatin in adult critically ill patients[J]. Chinese Journal of Drug Application and Monitoring, 2019, 16(2): 89-92.] DOI: 10.3969/j.issn.1672-8157.2019.02.008.

22.Deshayes S, Coquerel A, Verdon R. Neurological adverse effects attributable to β-lactam antibiotics: a literature review[J]. Drug Saf, 2017, 40(12): 1171-1198. DOI: 10.1007/s40264-017-0578-2.

23.代菲,舒丽芯,储藏,等.简述分析几种信号监测方法在药物不良事件中的应用[J].药学实践杂志, 2012, 30(5): 380-383. [Dai F, Shu LX, Chu C, et al. Brief analysis the application of several signal monitoring methods in adverse drug events[J]. Journal of Pharmaceutical Practice, 2012, 30(5): 380-383.] DOI: 10.3969/j.issn.1006-0111.2012.05.018.

24.于洪礼,逄瑜,邵波,等.我国基本药物不良反应报告与监测情况浅析[J].中国药物警戒, 2021, 18(8): 766-768, 775. [Yu HL, Pang Y, Shao B, et al. Current adverse drug reaction reporting and monitoring of essential medicines in china[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 766-768, 775.] DOI: 10.19803/j.1672-8629.2021.08.14.